Key terms
About EXAS
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EXAS news
Yesterday
4:45pm ET
Exact Sciences Announces Board Member Retirement
Apr 15
10:21am ET
Exact Sciences CFO’s resume ‘impressive,’ says William Blair
Apr 15
6:32am ET
Exact Sciences Appoints Aaron Bloomer as New CFO
Apr 15
6:02am ET
Exact Sciences names Aaron Bloomer as CFO, effective May 15
Apr 09
9:00pm ET
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
Apr 04
6:09am ET
Exact Sciences to supply individual cancer information to Mayo Clinic patients
Apr 03
8:21am ET
Exact Sciences removed from ‘Tactical Outperform’ list at Evercore ISI
Apr 03
6:03am ET
Citi opens ‘positive catalyst watch’ on Exact Sciences after competitor data
Apr 03
5:19am ET
Canaccord positive on Exact, Guardant after Freenome data
Apr 02
9:49am ET
Exact Sciences, Guardant rally after Freenome colorectal cancer test results
Apr 02
9:41am ET
Unusually active option classes on open April 2nd
Mar 28
6:09am ET
Exact Sciences’ Oncoguard Esophagus test shows efficacy in published study
Mar 21
11:06am ET
EXACT Sciences call volume above normal and directionally bullish
Mar 19
8:31am ET
Exact Sciences added to ‘Tactical Outperform’ list at Evercore ISI
Mar 19
2:40am ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Mar 13
5:04pm ET
Exact Sciences says Cologuard Plus test results published in NEJM
Feb 27
5:25am ET
Exact Sciences (EXAS) Receives a Buy from BTIG
Feb 26
8:00am ET
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
Feb 26
12:01am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), Teleflex (TFX) and Amgen (AMGN)
Feb 25
11:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Feb 22
8:34am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Moderna (MRNA) and Glaukos (GKOS)
Feb 22
8:10am ET
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Exact Sciences (EXAS) and DarioHealth (DRIO)
Feb 22
8:05am ET
Piper Sandler Sticks to Their Buy Rating for Exact Sciences (EXAS)
Feb 22
7:32am ET
Exact Sciences price target lowered to $90 from $100 at Canaccord
Feb 22
7:25am ET
Exact Sciences price target lowered to $85 from $90 at BTIG
Feb 22
7:04am ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)
Feb 22
5:50am ET
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN) and Exact Sciences (EXAS)
Feb 22
12:00am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 21
11:50pm ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Tandem Diabetes Care (TNDM)
Feb 21
10:46pm ET
Buy Rating Affirmed for Exact Sciences on Strong Quarterly Performance and Growth Potential
Feb 21
4:14pm ET
Exact Sciences sees FY24 revenue $2.81B-$2.85B, consensus $2.83B
No recent press releases are available for EXAS
EXAS Financials
Key terms
Ad Feedback
EXAS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EXAS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range